Xeris Biopharma Holdings (XERS) EPS (Weighted Average and Diluted) (2021 - 2026)
Xeris Biopharma Holdings (XERS) reported EPS (Weighted Average and Diluted) of $0.01 for Q1 2026, up 116.67% on a YoY basis from $0.0 in Q1 2025, and down 85.71% quarter-over-quarter from $0.07 in Q4 2025.
Xeris Biopharma Holdings (XERS) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Xeris Biopharma Holdings has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at $0.01 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 116.67% year-over-year to $0.01; the trailing twelve-month figure through Mar 2026 stood at $0.07 (up 123.33% YoY), and the FY2025 full-year result was $0.0, up 100.87% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.01, down from $0.07 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.07 in Q4 2025, with the low at -$0.25 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.09 across 5 years, with a median of -$0.1 in 2022.
- Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) slipped 22.22% — and 2025, when it soared 333.33%.
- Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) stood at -$0.1 in 2022, then gained by 10.0% to -$0.09 in 2023, then jumped by 66.67% to -$0.03 in 2024, then soared by 333.33% to $0.07 in 2025, then sank by 85.71% to $0.01 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.01 (Q1 2026), $0.07 (Q4 2025), and $0.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Xeris Biopharma Holdings | 1.11 Bn | 994.95 Mn | 72.55 Mn | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.01 |
| Dec 31, 2025 | 0.07 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | -0.01 |
| Mar 31, 2025 | -0.06 |
| Dec 31, 2024 | -0.03 |
| Sep 30, 2024 | -0.11 |
| Jun 30, 2024 | -0.10 |
| Mar 31, 2024 | -0.14 |
| Dec 31, 2023 | -0.09 |
| Sep 30, 2023 | -0.09 |
| Jun 30, 2023 | -0.14 |
| Mar 31, 2023 | -0.12 |
| Dec 31, 2022 | -0.10 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | -0.19 |
| Mar 31, 2022 | -0.25 |
| Dec 31, 2021 | -0.44 |
| Sep 30, 2021 | -0.39 |
| Jun 30, 2021 | -0.41 |